<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610423</url>
  </required_header>
  <id_info>
    <org_study_id>434476</org_study_id>
    <nct_id>NCT05610423</nct_id>
  </id_info>
  <brief_title>Covid-19 Vaccine Associated Myocarditis and Pericarditis in Norway</brief_title>
  <official_title>Covid-19 Vaccine Associated Myocarditis and Pericarditis in Norway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Medicines Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a national multicenter study in Norway investigating of individuals with Covid-19&#xD;
      vaccine associated myocarditis (VAM) and pericarditis in Norway.&#xD;
&#xD;
      The main objective is to validate the reported possible cases of Covid-19 vaccine associated&#xD;
      myo-and pericarditis in Norway as well as investigate for predisposing factors and risk&#xD;
      factors for developing these vaccine adverse events.&#xD;
&#xD;
      Furthermore, patients with confirmed Covid-19 VAM, will be invited to participate in a&#xD;
      prospective cohort study, investigating for cardiac long-term adverse effects 1 year and 2&#xD;
      years after vaccine-associated myocarditis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myocarditis and pericarditis following vaccination with Covid-19 vaccines has been reported&#xD;
      as rare but unexpected and potentially severe vaccine adverse events.&#xD;
&#xD;
      In Norway, all vaccines administrated are registered in the national vaccine registry&#xD;
      (SYSVAK). All in-hospital diagnoses are reported in a national diagnosis registry (NPR).&#xD;
      These complete national high-quality registers allow linking diagnosis of myocarditis and&#xD;
      pericarditis to vaccine data (date, product, dose number) on an individual level.&#xD;
&#xD;
      Oslo University Hospital, in collaboration with the Norwegian Institute of Public Health and&#xD;
      the Norwegian Medicines Agency, will perform a study consisting of 2 parts:&#xD;
&#xD;
      Part 1 &quot;Validation study&quot;:&#xD;
&#xD;
      Eligible patients for inclusion are all individuals with suspected / reported Covid - 19&#xD;
      vaccine associated pericarditis and myocarditis in Norway from 2021 and onwards. Patients&#xD;
      will be identified by linking data from the Norwegian Patient registry NPR (ICD-10 diagnostic&#xD;
      codes for pericarditis and myocarditis) and the Immunization registry (SYSVAK) (&lt; 90 days&#xD;
      since vaccination). The diagnosis of Covid-19 vaccine associated pericarditis and myocarditis&#xD;
      will then be confirmed or rejected by medical record search according to international&#xD;
      accepted Brighton criteria. The Brighton collaboration criteria provide evidence levels of&#xD;
      diagnostic certainty of myocarditis and pericarditis based on cardiac signs and symptoms,&#xD;
      cardiac enzymes, ECG findings, imaging studies and histopathology.The criteria is used to&#xD;
      distinguish between suspected, probable and confirmed diagnosis of myocarditis and&#xD;
      pericarditis. Patients with another more likely reason for confirmed myocarditis or&#xD;
      pericarditis by Brighton will not be classified with Covid-19 vaccine associated myocarditis&#xD;
      (VAM) or pericarditis, respectively.&#xD;
&#xD;
      Part 2 &quot;Clinical follow-up study&quot; All patients identified in the validation study with&#xD;
      confirmed Covid-19 VAM will be invited to participate in the prospective clinical follow-up&#xD;
      study (all age groups, both sexes, all geographical areas of Norway). Inclusion wil be by&#xD;
      informed consent. Data collection, symptom reporting and cardiac examinations (clinical&#xD;
      examination, ECG, 24 hours Holter ECG, echocardiography, cardiac magnetic resonance imaging)&#xD;
      will be performed at 1 and 2 years after a diagnosis of Covid -19 VAM. Blood analyses will be&#xD;
      performed and a blood sample stored in a biobank in consenting participants. Clinical&#xD;
      endpoints will be collected at 1 and 2 years follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2032</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2032</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of myocardial scar</measure>
    <time_frame>1 year post myocarditis</time_frame>
    <description>Quantification of myocardial scar by cardiac magnetic resonance (CMR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduced myocardial function</measure>
    <time_frame>1 year post myocarditis</time_frame>
    <description>Assessment of myocardial function by echocardiography and CMR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of supraventricular arrhythmias</measure>
    <time_frame>1 year post myocarditis</time_frame>
    <description>Presence, frequency and type supraventricular arrhythmias detected on ECG and 24 hours Holter ECG recording</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of ventricular arrhythmias</measure>
    <time_frame>1 year post myocarditis</time_frame>
    <description>Presence, frequency and type of ventricular arrhythmias detected on ECG and 24 hours Holter ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persisting cardiac symptoms.</measure>
    <time_frame>2 years post myocarditis</time_frame>
    <description>Participant reporting shortness of breath,chest pain, dizziness, syncope, fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All cause death</measure>
    <time_frame>1 year post myocarditis</time_frame>
    <description>Register death by cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of myocardial scar</measure>
    <time_frame>2 years post myocarditis</time_frame>
    <description>Quantification of myocardial scar by cardiac magnetic resonance (CMR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced myocardial function</measure>
    <time_frame>2 years post myocarditis</time_frame>
    <description>Assessment of myocardial function by echocardiography and CMR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of supraventricular arrhythmias</measure>
    <time_frame>2 years post myocarditis</time_frame>
    <description>Presence, frequency and type supraventricular arrhythmias detected on ECG and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of ventricular arrhythmias</measure>
    <time_frame>2 years post myocarditis</time_frame>
    <description>Presence, frequency and type of ventricular arrhythmias detected on ECG and 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persisting cardiac symptoms.</measure>
    <time_frame>2 years post myocarditis</time_frame>
    <description>Participant reporting shortness of breath,chest pain, dizziness, syncope, fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>2 years post myocarditis</time_frame>
    <description>Register death by cause</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myocarditis</condition>
  <arm_group>
    <arm_group_label>Covid-19 vaccine associated myocarditis</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>No intervention. Observational study only</description>
    <arm_group_label>Covid-19 vaccine associated myocarditis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood will be drawn from study participants for routine biochemistry. By separate consent&#xD;
      from participants, blood will be stored in a study specific biobank pending analyses,&#xD;
      including genetic analyses by whole genome sequencing to search for genetic variants&#xD;
      associated with vaccine associated myocarditis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Covid-19 vaccine associated myocarditis and pericarditis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Part 1 Individuals identified with possible Covid-19 vaccine associated myocarditis and&#xD;
        pericarditis, by linkage of diagnosis of myocarditis and pericarditis (from Norwegian&#xD;
        Patient Registry, NPR) and vaccination data (Immunization registry, SYSVAK).&#xD;
&#xD;
        Part 2.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed myocarditis (definite, probable, possible) by Brighton criteria &lt; 90 days&#xD;
             after either Covid-19 vaccine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other more likely cause of myocarditis, including Covid-19 infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina E Hasselberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Nina Eide Hasselberg</investigator_full_name>
    <investigator_title>Consultant cardiologist</investigator_title>
  </responsible_party>
  <keyword>Vaccine side effect</keyword>
  <keyword>Long term cardiac follow up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
    <mesh_term>Pericarditis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

